Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)
Shenzhen, CN
Established in 1992 and headquartered in Shenzhen, China, Shenzhen Kangtai Biological Products Co., Ltd. is dedicated to the research, development, manufacturing, and commercialization of a diverse array of human vaccines across the Chinese market. The company's extensive portfolio includes essential immunizations such as the SARS-COV-2 vaccine, recombinant hepatitis B vaccine, and various pneumococcal disease vaccines (including 13-valent conjugate and 23-valent polysaccharide types). Its offerings also encompass combined vaccines like diphtheria, tetanus, acellular pertussis, and haemophilus influenzae type b, in addition to specific haemophilus influenzae type b conjugate, measles and rubella live attenuated, rabies, and inactivated poliomyelitis vaccines. Internationally, the company has partnered with YTB and Yong Tai Berhad to develop and commercialize a Covid-19 inactivated vaccine specifically for Malaysia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.95% | -5.29% | -9.93% | -15.61% | -21.12% | -14.01% | -11.13% | -54.56% | -88.61% | +669.70% | +669.70% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | +1 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.8% Q1'26: -2.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-66.7% Q1'26: +49.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.7% Q1'26: -32.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.2% Q1'26: +7.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.8% Q1'26: +1.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.6% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.52× ★ Q1'26: 10.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.16B
est: 1.05B (+10.9%)
|
2.02B
est: 2.03B (-0.6%)
|
1.94B
est: 2.10B (-7.5%)
|
2.26B
est: 2.50B (-9.7%)
|
3.69B
est.
|
3.65B
est: 3.23B (+13.1%)
|
3.48B
est: 2.95B (+17.9%)
|
3.16B
est: 2.95B (+7.1%)
|
2.65B
est: 2.91B (-8.7%)
|
2.67B
est: 2.70B (-1.0%)
|
2.77B
2.58B – 2.91B
+2.7% YoY
|
3.04B
2.74B – 3.37B
+9.5% YoY
|
3.34B
3.29B – 3.38B
+10.0% YoY
|
| EBITDA |
298.32M
est: 290.27M (+2.8%)
|
571.45M
est: 562.35M (+1.6%)
|
755.44M
est: 582.65M (+29.7%)
|
867.68M
est: 694.15M (+25.0%)
|
1.02B
est.
|
1.90B
est: 894.91M (+112.2%)
|
1.26B
est: 769.33M (+63.2%)
|
-27.65M
est: 769.33M (-103.6%)
|
585.16M
est: 758.08M (-22.8%)
|
564.86M
est: 704.62M (-19.8%)
|
723.37M
673.55M – 760.07M
+2.7% YoY
|
791.79M
715.64M – 879.33M
+9.5% YoY
|
870.76M
859.02M – 882.50M
+10.0% YoY
|
| EBIT |
240.44M
est: 208.47M (+15.3%)
|
513.55M
est: 403.87M (+27.2%)
|
672.46M
est: 418.45M (+60.7%)
|
774.75M
est: 498.52M (+55.4%)
|
735.15M
est.
|
1.49B
est: 642.70M (+132.6%)
|
1.05B
est: 474.84M (+122.0%)
|
-228.60M
est: 474.84M (-148.1%)
|
274.49M
est: 467.90M (-41.3%)
|
164.50M
est: 434.90M (-62.2%)
|
446.48M
415.73M – 469.13M
+2.7% YoY
|
488.71M
441.71M – 542.74M
+9.5% YoY
|
537.45M
530.20M – 544.70M
+10.0% YoY
|
| Net Income |
214.70M
est: 163.65M (+31.2%)
|
435.69M
est: 555.47M (-21.6%)
|
574.51M
est: 601.23M (-4.4%)
|
679.19M
est: 808.72M (-16.0%)
|
1.28B
est.
|
1.26B
est: -112.56M (+1,222.4%)
|
861.30M
est: 516.21M (+66.9%)
|
-132.71M
est: 516.21M (-125.7%)
|
201.65M
est: 567.75M (-64.5%)
|
70.33M
est: 64.43M (+9.2%)
|
156.81M
139.95M – 173.68M
+143.4% YoY
|
263.65M
222.48M – 276.12M
+68.1% YoY
|
347.90M
155.66M – 518.34M
+32.0% YoY
|
| SGA |
705.67M
est: 419.21M (+68.3%)
|
1.15B
est: 812.14M (+41.7%)
|
943.74M
est: 841.46M (+12.2%)
|
1.03B
est: 1.00B (+2.8%)
|
1.48B
est.
|
819.80M
est: 1.29B (-36.6%)
|
1.51B
est: 1.12B (+34.7%)
|
1.32B
est: 1.12B (+17.7%)
|
1.25B
est: 1.10B (+13.8%)
|
931.81M
est: 1.02B (-9.0%)
|
1.05B
978.39M – 1.10B
+2.7% YoY
|
1.15B
1.04B – 1.28B
+9.5% YoY
|
1.26B
1.25B – 1.28B
+10.0% YoY
|
| EPS |
0.22
est: 0.15 (+50.6%)
|
0.44
est: 0.50 (-11.3%)
|
0.57
est: 0.54 (+6.2%)
|
0.64
est: 0.72 (-11.3%)
|
1.15
est.
|
1.16
est: -0.10 (+1,300.0%)
|
0.77
est: 0.46 (+66.3%)
|
-0.12
est: 0.46 (-125.9%)
|
0.18
est: 0.48 (-62.9%)
|
0.06
est: 0.06 (+9.1%)
|
0.13
0.12 – 0.15
+143.4% YoY
|
0.21
0.19 – 0.24
+59.0% YoY
|
0.30
0.13 – 0.44
+38.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.02% | 3.6K | 0.65% |
| 2 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 5.3K | 0.15% |
| 3 | State Street SPDR S&P China ETF GXC | 0.01% | 39.2K | 0.59% |
| 4 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 97.5K | 0.19% |
| 5 | Franklin FTSE China ETF FLCH | 0.00% | 11.5K | 0.19% |
| 6 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 15.0K | 0.40% |
| 7 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.00% | 8.5K | 0.49% |
| 8 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 182.6K | 0.06% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 112.2K | 0.39% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 38.4K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cui Dong Huang | Accounting Supervisor & Head of Accounting Department | — | — |
| Jianhui Gan | Vice President | — | male |
| Jiankai Liu | Vice President & Non-Independent Director | — | male |
| Jianying Ma | Chief Financial Officer | — | male |
| Jin Tao | Vice President & Board Secretary | — | female |
| Qi Nie Xiao | Vice President | — | male |
| Xiang Miao | President & Non-Independent Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300601.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
